

Replication and Heritability of Prostate Cancer Risk Variants: Impact of Population-Specific Factors

Victor Virlogeux^{1,2}, Rebecca E. Graff¹, Thomas J. Hoffmann^{1,3}, and John S. Witte^{1,3,4,5}

Abstract

Background: Prostate cancer incidence and mortality rates vary across populations, with African American men exhibiting the highest rates. To date, genome-wide association studies have identified 104 SNPs independently associated with prostate cancer in men of European ancestry.

Methods: We investigated whether the ability to replicate findings for these 104 SNPs in African American, Asian, and Latino populations depends on variation in risk allele frequencies (RAF), strength of associations, and/or patterns of linkage disequilibrium (LD) at the associated loci. We extracted estimates of effect from the literature, and determined RAF and LD information across the populations from the 1000 Genomes Project.

Results: Risk variants were largely replicated across populations. Relative to Europeans, 83% had smaller effect sizes among

African Americans and 73% demonstrated smaller effect sizes among Latinos. Among Asians, however, 56% showed larger effect sizes than among Europeans. The largest difference in RAFs was observed between European and African ancestry populations, but this difference did not impact our ability to replicate. The extent of LD within 250 kb of risk loci in Asian ancestry populations was suggestively lower for variants that did not replicate ($P = 0.013$).

Conclusions: Despite substantial overlap in prostate cancer risk SNPs across populations, the variation in prostate cancer incidence among different populations may still in part reflect unique underlying genetic architectures.

Impact: Studying different ancestral populations is crucial for deciphering the genetic basis of prostate cancer. *Cancer Epidemiol Biomarkers Prev*; 24(6); 938–43. ©2015 AACR.

Introduction

Prostate cancer is the second most commonly diagnosed cancer among men globally and the sixth most common cause of cancer death (1, 2). Prostate cancer incidence and mortality rates vary substantially across regions of the world. Rates are highest in developed countries and lowest in developing areas of Asia and Africa (2, 3). In the United States, African Americans have an incidence rate 1.6 times higher and a mortality rate 2.5 times higher than that in men of European Ancestry (4). This variation may reflect a number of factors, including distinctive screening practices, environment, and genetics (5–9).

Genetics are especially important given that prostate cancer is the most heritable common cancer, with a recent twin study estimating a heritability of 58% (95% confidence intervals, 52%–63%; ref. 10).

Moreover, risk increases between 2- and 4-fold for first-degree male relatives of affected individuals (11). Genome-wide association studies (GWAS) have identified over 100 SNPs that are associated with risk of prostate cancer (12). Although a majority of these GWAS have been conducted among men of European ancestry, many of the SNPs that they have identified are also associated with prostate cancer risk among men of other ancestries (13, 14). Still, some SNPs have not replicated and the strength of associations for those that have is often variable across populations. Risk allele frequencies (RAF) of prostate cancer-associated SNPs also show substantial variation across populations. These disparities may drive population differences in heritability and may in part explain the epidemiologic variations in disease risk (15).

In this study, we evaluated whether the risk SNPs identified from previous GWAS help explain the race/ethnicity patterns of prostate cancer by analyzing data from existing studies of European, African American, Asian, and Latino populations. We compared these populations with respect to risk SNP allele frequencies, strength of associations, linkage disequilibrium (LD) patterns, and heritability. We aimed to help clarify whether SNPs identified mostly among European ancestry populations can explain epidemiologic variations in prostate cancer and if further studies are necessary to discover prostate cancer risk SNPs in other ancestral populations.

Materials and Methods

Replication of risk SNPs

We evaluated 104 SNPs that were previously identified as significantly associated with an increased risk of developing

¹Department of Epidemiology and Biostatistics, University of California, San Francisco, California. ²Department of Biology, Ecole Normale Supérieure de Lyon, Lyon, France. ³Institute for Human Genetics, University of California, San Francisco, California. ⁴Department of Urology, University of California, San Francisco, California. ⁵UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Corresponding Author: John S. Witte, University of California San Francisco, 1450 3rd Street, San Francisco, CA 94158. Phone: 415-502-6882; Fax: 415-476-1356; E-mail: jwitte@ucsf.edu

doi: 10.1158/1055-9965.EPI-14-1372

©2015 American Association for Cancer Research.

prostate cancer in men of European ancestry (12, 14, 16–30). We determined the corresponding odds ratios (ORs) for each SNP from the literature for European, African American, Asian, and Latino populations (13, 16–28, 30–41). For African Americans, the ORs were obtained from two recent studies that evaluated the risk of prostate cancer for 82 and 21 SNPs, respectively (one SNP had no available data for African Americans from either study; refs. 13, 14). For Asians and Latinos, only a subset of the SNPs was available from the literature: 75 of 104 SNPs for Asians and 71 of 104 SNPs for Latinos (13, 14, 16–20, 22–28, 30–41). When several studies for one SNP were available for these two populations, an inverse variance weighted average of the ORs was calculated.

We evaluated whether the risk SNPs had similar estimates of association with prostate cancer across ancestral populations, comparing the European ancestry population with each other population. We also stratified these comparisons by whether the ORs were nominally significantly associated with prostate cancer in the non-European populations ($P < 0.05$). We then assessed whether the distribution of risk SNP association P values in the African American, Asian, and Latino populations clustered around small values, which would be suggestive of replication.

We also estimated the population-specific RAF of each variant associated with prostate cancer from the 1000 Genomes Project using the broad population groupings for European, Asian, and Latino (42). For the African American population, we estimated the RAF to be $0.2 \times \text{RAF (European)} + 0.8 \times \text{RAF (African)}$, reflecting the approximate genome-wide admixture of European and African ancestral populations (43).

Impact of linkage disequilibrium on replication

GWAS are designed to assay SNPs that "tag" potentially causal variants across the genome via the phenomenon of LD. Because patterns of LD vary across ancestral populations, the ability to replicate prostate cancer hits can depend on how well measured risk SNPs cover causal variants in a given population. To evaluate this, for each population we estimated the LD using the pairwise correlation (r^2) between each index risk SNP and each neighboring SNP within 250 kb upstream or downstream (500 kb window total) using data from the 1000 Genomes Project. We calculated the mean (and median) r^2 value for each risk locus window, excluding pairs with very low LD ($r^2 < 0.05$). Next, we stratified the risk loci by whether they were replicated in the different populations, and calculated the average mean r^2 values within each stratum. Doing so revealed whether LD patterns differ based on whether prostate cancer risk SNPs are successfully replicated across populations. To assess the sensitivity of our results to window size, we also analyzed the LD patterns using a smaller window size: 100 kb up- and downstream from the risk SNP (total window size = 200 kb).

Ancestral differences in heritability explained

We estimated how much prostate cancer heritability is explained by the risk SNPs—and how this varies by ancestral population—with a multifactorial liability threshold model (44–47). We calculated heritability from the RAF and ORs for the risk SNPs, assuming that the overall lifetime risk of developing prostate cancer is 15% (based on the literature) and that the sibling recurrence risk (λ_s) is 3.14 (44, 48). Here, we used the INDI-V tool (<http://cnsgenomics.com/software>; ref. 49). All other statistical

analyses were performed with R version 3.1.1 (R Development Core Team).

Results

Figure 1 plots the logarithms of the ORs (logOR) for the associations of the 104 risk SNPs with prostate cancer, comparing the European ancestry population to the African American, Asian, and Latino populations (details for each risk SNP are given in Supplementary Table S1 and Supplementary Fig. S1). Overall, most of the logORs were larger in the European ancestry population, as expected since this is the population in which they were discovered (Fig. 1). LogORs for risk SNPs nominally associated with prostate cancer ($P < 0.05$, blue in Fig. 1) in the non-European populations were generally larger than those not associated with disease ($P > 0.05$, red in Fig. 1). Relative to the African American population, 83% of the logORs (85/103) were larger in the European population; nevertheless, 41% (41/103) of these SNPs had $P < 0.05$ (blue, Fig. 1) and 68% (28/41) of these nominally significant SNPs had a higher RAF in the African Americans ($P = 0.008$). In contrast, relative to Asians, only 44% of the logORs (32/75) were larger in the European population, 56% (42/75) of the SNPs were replicated ($P < 0.05$, blue, Fig. 1), and 52% (22/42) of these nominally significant SNPs had a higher RAF in the Asians ($P = 0.89$). Relative to Latinos, 73% of the logORs (52/71) were larger in the European population, 31% (22/71) of these SNPs had $P < 0.05$ (blue, Fig. 1), and 59% (13/22) of these nominally significant SNPs had a higher RAF in the Latinos ($P = 0.23$).


For the replicated SNPs ($P < 0.05$), fitting a linear regression to the logORs gave correlations of $r^2 = 0.51$ ($P = 6.8 \times 10^{-4}$), $r^2 = 0.64$ ($P = 5.3 \times 10^{-6}$), and $r^2 = 0.23$ ($P = 0.30$) between the European ancestry population and the African American, Asian, and Latino populations, respectively (blue dashed lines in Fig. 1). When repeating this analysis for the nonreplicated SNPs, there was no correlation for the African American or Asian populations ($P = 0.90$ and $P = 0.81$, respectively), but there was for the Latino population: $r^2 = 0.45$ ($P = 0.001$). The difference in results for the Latino population likely reflects the small number of replicated SNPs (15); the slopes of the lines for the replicated (blue) and nonreplicated (red) SNPs were very similar when comparing the European to Latino populations. These lines suggest that the Latino population had a suggestive trend toward replication of all of the risk SNPs.

To further evaluate potential replication, we plotted the association P values for each of the three non-European ethnic groups (Fig. 2). Doing so showed a clear clustering of small P values, with the remaining P values uniformly distributed.

As expected based on evolutionary history, we found that the largest difference in RAF was between the European and African American populations. The overall mean RAF was slightly higher among African Americans (2.5%) but not significantly different ($P = 0.46$). The mean difference in RAF between the two populations was higher (6.7%) when evaluating only the SNPs significantly associated with prostate cancer in the African American population ($P < 0.05$). The Asian and Latino populations had slightly higher (albeit nonsignificant) mean RAF than the European population when comparing the SNPs significantly associated with prostate cancer in these populations (0.4% and 2.2%, respectively).

To investigate patterns of LD around the risk SNPs, we looked at pairwise r^2 within 500 kb windows, and compared the mean

Virlogeux et al.

**Figure 1.**

Genetic effects of SNPs nominally associated with prostate cancer ($P < 0.05$) and not associated with prostate cancer ($P > 0.05$) are correlated between EUR and the different ethnic groups (AFR, ASN, and LAT). Correlations between log odds ratios of SNPs associated with prostate cancer in the different comparisons are reported here with AFR/EUR in A, ASN/EUR in B, and LAT/EUR in C. Significant SNPs associated with prostate cancer ($P < 0.05$) are reported in blue and SNPs with $P > 0.05$ are reported in red. Linear regression between the log odds ratio estimates of SNPs for both populations is represented with blue lines for the replicated and red lines for nonreplicated SNPs. For the nonreplicated SNPs, $r^2 = 0.017$ and $P = 0.899$ for AFR/EUR, $r^2 = 0.044$ and $P = 0.809$ for ASN/EUR, and $r^2 = 0.448$ and $P = 0.001$ for LAT/EUR. AFR, African American; EUR, European; ASN, Asian; LAT, Latino.

r^2 among the European versus each of the three other populations. Comparing European to African Americans, the mean r^2 was nominally ($P < 0.05$) higher among Europeans for 74% of the risk loci (75/102), but was lower for only 12% (12/102) ($P < 0.001$ testing the counts of higher vs. lower mean r^2 in the populations). Means of r^2 , number of pairs of SNPs before and after filtering on low LD ($r^2 < 0.05$), and data sources are given in Supplementary Table S2; details for each locus are given in Supplementary Fig. S2. There was no overall difference when comparing European with Asian populations: the mean r^2 was higher among Europeans for 35% of the risk loci (35/101) and was lower for 34% (34/101; $P = 0.88$). Comparing European with Latinos, we observed fewer risk SNPs with increased r^2 among the Europeans: the mean r^2 was higher among Europeans for 23% of the risk loci (24/104), but was lower for 34% (35/104; $P = 0.09$).

We further evaluated LD patterns stratified by whether SNPs were associated with prostate cancer ($P < 0.05$) in each of the three non-European ancestral populations (Table 1; note that the European population means of r^2 values differed slightly depending on what SNP association information was available for a given comparison population; hence they were lower in the Asian and Latino populations). As expected, the African American population had the lowest mean LD around the risk loci (Table 1). However, this LD did not differ based on whether the risk SNPs were replicated in African Americans ($P = 0.37$). In addition, no significant difference in LD among Europeans was observed between these replicated and nonreplicated SNPs ($P = 0.19$). However, we did observe a trend ($P = 0.087$) toward such an LD difference with a smaller window size (200 kb instead of 500 kb). This suggests that among African Americans, the similarity between the LD for the replicated and nonreplicated SNPs may simply reflect lower overall LD in this population. In contrast, a higher mean r^2 value was observed for replicated versus nonreplicated SNPs in the Asian population ($P = 0.013$), whereas no difference in the LD among Europeans was observed between these replicated and nonreplicated SNPs ($P = 0.60$). Slightly weaker but similar results were observed in the Latino population with a higher mean r^2 value for replicated versus nonreplicated SNPs ($P = 0.054$), whereas no such difference in the LD among Europeans was observed ($P = 0.15$). These results for the Asian and Latino comparisons were essentially unchanged when using a smaller window (200 kb total; note that the GWAS arrays generally used for these studies have higher coverage in European than in other ancestral populations).

To assess how much heritability is explained by the risk SNPs and how it differs by ethnic group, we estimated the total proportion of heritability explained by the set of SNPs available for each population. The total heritability proportion for the 103 SNPs was 0.20 for Europeans and 0.10 for African Americans. The total heritability proportion for the 75 SNPs available for the Asian population was 0.17 for Europeans and 0.28 for Asians. Finally, the total heritability proportion for the 71 SNPs available for the Latino population was 0.14 for Europeans and 0.11 for Latinos.

Discussion

We found that most ORs for the prostate cancer risk SNPs were larger in Europeans than in African Americans or Latinos, but were similar between Europeans and Asians. We also observed that, for SNPs that replicated, the effect sizes in the European population




Figure 2. Enrichment for small *P* values among SNPs that are significantly associated in European GWAS in the different ethnic groups.

were correlated with effect sizes in the African American and Asian populations. The extent of LD in Asians and Latinos was lower in SNPs that did not replicate in these populations. A slight trend of lower LD was seen comparing the European with African American populations with a smaller window size. The prostate cancer risk SNPs appear to explain twice as much heritability in Europeans than African Americans (20% vs. 10%). In contrast, a higher estimated heritability was found in Asians than Europeans (28% vs. 17%; 75 risk SNPs) and no clear difference was observed between Europeans and Latinos (71 risk SNPs).

The results observed here regarding the strength of associations and extent of heritability are in part due to the discovery of the 104 risk SNPs in populations of European ancestry. Indeed, 60% of

variants for African Americans, 44% of variants for Asians, and 69% of variants for Latinos were not replicated at $P < 0.05$, which suggests that either these variants are not adequately correlated with the underlying biologically relevant variant (8) or that further studies with larger sample sizes are required to have sufficient power to detect associations with these specific variants. Moreover, a winner's curse effect could have contributed to the differences observed regarding the strength of associations across the populations (50).

Our observation that regions exhibiting higher LD were more likely to replicate across populations may reflect better tagging of the potential causal variants by the GWAS arrays in high LD regions. This result supports the hypothesis that the most conserved regions between different ancestral populations (high LD) may be more associated with prostate cancer than the regions in which the LD is lower (e.g., if the potential causal variants are not necessarily shared across populations). Thus, when attempting to replicate results across different ancestral populations, one may need to fine map a broad region surrounding the index association finding.

Recent work has explored whether extensive fine mapping of prostate cancer risk loci in nondiscovery ethnic groups can improve replication (13). When fine mapping each European prostate cancer locus in search of more strongly associated risk SNPs in African Americans, the number of replicated SNPs ($P < 0.05$) increased from 30 of 82 (37%) to 44 of 82 (54%), and two of the 14 newly replicated variants in high LD with the index SNP (defined as $r^2 > 0.80$) may have actually been specific to African Americans (13). These results highlight the value of trans-ethnic fine mapping of GWAS loci to help identify causal variants that may vary across ethnic populations.

The differences in associations of SNPs with prostate cancer across the ancestral populations could also be related in part to the flip-flop phenomenon, which occurs when independent studies show associations between a SNP and trait for different alleles. This phenomenon may be attributable to varying LD architectures across populations (51). Another potential issue here is that although the 1000 Genomes Project includes many ethnic subgroups and tries to be representative of all ancestral populations, our findings depend on the accuracy of its information.

Concerning heritability, many previous studies have focused on the heritability of prostate cancer in family cohort and twin studies. The recent Nordic Twin Study of Cancer cohort (10) estimated that additive genetic effects account for 58% of the heritability of liability of developing prostate cancer, currently the highest estimate of heritability for any common cancer (52). Another recent study, based on 77 of the GWAS risk SNPs, estimated that these variants explain approximately 30% of familial risk (16). In contrast, we estimated the total heritability of prostate cancer attributed to a larger set of 103 SNPs to be 20% in the European population. This highlights the difference between estimating familiarity and heritability, although some may incorrectly interpret these estimates as exchangeable (53). For the Asian population, we estimated an even higher total heritability proportion due to the prostate cancer risk variants (28%). Taken together, our findings confirm that further studies are needed to determine more accurate effect estimates across the different populations.

Heritability was calculated for each risk SNP, and provides no information about the actions of and interactions between individual genes. (53) Moreover, although our evaluation of LD gives

Table 1. Comparison of LD at prostate cancer risk loci detected in European ancestry populations that were replicated versus not replicated in other ancestral populations

Test population	Mean r^2		P
	Replicated SNPs	Not replicated	
African Americans			
Number of SNPs	41	60	
AFR	0.13 ± 0.06	0.12 ± 0.05	0.37
EUR	0.21 ± 0.10	0.18 ± 0.09	0.19
Asian			
Number of SNPs	42	32	
ASN	0.24 ± 0.12	0.18 ± 0.09	0.01
EUR	0.21 ± 0.09	0.23 ± 0.09	0.60
Latino			
Number of SNPs	22	49	
LAT	0.21 ± 0.09	0.18 ± 0.08	0.05
EUR	0.22 ± 0.10	0.19 ± 0.09	0.15

NOTE: LD is measured by the correlation coefficient (r^2) between the index SNP reported as associated with prostate cancer in a European ancestry population and all other SNPs within a 500-kb window (250 kb on either side of the index SNP). For each index SNP in the different comparisons, a pair of mean r^2 (one for each population) is calculated using all the r^2 corresponding to the same pair's SNP/index SNP in both populations. For each pair SNP/index SNP, when both r^2 were under 0.05 in both populations, the pair was excluded from the analysis. LD is based on data from the 1000 Genomes Project; further details are given in Supplementary Table S2.

Data for each mean of each index SNP are reported in Supplementary Table S2. Mean r^2 is the mean of the mean for each locus.

For the AFR/EUR comparison, the subgroup of index SNPs associated with prostate cancer includes SNPs that are directly associated with prostate cancer ($N = 27$) and SNPs in high LD with another SNP associated with prostate cancer ($N = 14$).

Abbreviations: AFR, African American; EUR, European; ASN, Asian; LAT, Latino.

an idea of the global dynamic architecture of the genomic regions included in this study, it may also be interesting to conduct an evaluation of SNP-SNP interactions in the different populations in an attempt to better explain risk patterns across race/ethnicity groups. Indeed, Lin and colleagues studied the SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness and observed an association between five SNP-SNP interactions in three gene pairs and more aggressive prostate cancer (54). This approach is also supported by the genomic repartition of the SNPs associated with prostate cancer with some "hotspot" regions such as *8q24*, where the heritability

explained seems to be higher than in other genomic regions (Supplementary Fig. S3).

This study evaluates the LD and heritability across multiple populations for a set of SNPs associated with prostate cancer. Combining results from several studies with genomic data from the 1000 Genomes Project may help limit potential biases arising from individual GWAS (55). Although only some of the risk SNPs replicated across populations, the variation in associations across populations does not appear to explain the ethnic variation in prostate cancer risk. This situation is not unique to prostate cancer; difficulties replicating results across ethnic groups have been observed for other cancers (e.g., breast) as well as traits such as body mass index (56). Larger scale studies of ethnically diverse populations should help us further clarify these issues. Moreover, efforts are still needed to detect risk SNPs that are of particular importance and potentially unique to men of African and other ancestries, such as some of those at loci on chromosomal regions *8q24* and *17q21* (9, 26).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: V. Virlogeux, J.S. Witte

Development of methodology: V. Virlogeux, J.S. Witte

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): V. Virlogeux

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): V. Virlogeux, T.J. Hoffmann, J.S. Witte

Writing, review, and/or revision of the manuscript: V. Virlogeux, R.E. Graff, T.J. Hoffmann, J.S. Witte

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V. Virlogeux

Study supervision: V. Virlogeux

Grant Support

This work was supported by NIH grants CA112355, CA127298, and CA088164.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 12, 2014; revised February 24, 2015; accepted March 13, 2015; published OnlineFirst March 25, 2015.

References

- Baade PD, Youlten DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. *Mol Nutr Food Res* 2009;53:171-84.
- Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol* 2012;61:1079-92.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008;58:71-96.
- Brawley OW. Prostate cancer epidemiology in the United States. *World J Urol* 2012;30:195-200.
- Punnen S, Hardin J, Cheng I, Klein EA, Witte JS. Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. *PLoS ONE* 2011;6:e27711.
- Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP, et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. *PLoS ONE* 2010;5:e8736.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011;61:69-90.
- Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. *PLoS Genet* 2011;7:e1001387.
- Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. *Nat Genet* 2011;43:570-3.
- Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, et al. The heritability of prostate cancer in the nordic twin study of cancer. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol* 2014;23:2303-10.
- Hemminki K. Familial risk and familial survival in prostate cancer. *World J Urol* 2012;30:143-8.
- Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, et al. The genetic epidemiology of prostate cancer and its clinical implications. *Nat Rev Urol* 2014;11:18-31.
- Han Y, Signorello LB, Strom SS, Kittles RA, Rybicki BA, Stanford JL, et al. Generalizability of established prostate cancer risk variants in men of African ancestry. *Int J Cancer* 2015;136:1210-7.

14. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, et al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nat Genet* 2014;46:1103–9.
15. Jiao S, Peters U, Berndt S, Brenner H, Butterbach K, Caan BJ, et al. Estimating the heritability of colorectal cancer. *Hum Mol Genet* 2014;23:3898–905.
16. Eeles RA, Olama AAA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nat Genet* 2013;45:385–91, 391e1–2.
17. Kote-Jarai Z, Olama AAA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. *Nat Genet* 2011;43:785–91.
18. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. *Nat Genet* 2008;40:281–3.
19. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. *Nat Genet* 2009;41:1116–21.
20. Lindström S, Schumacher FR, Campa D, Albanes D, Andriole G, Berndt SI, et al. Replication of five prostate cancer loci identified in an Asian population—results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol* 2012;21:212–6.
21. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. *Hum Mol Genet* 2011;20:3867–75.
22. Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. *Nat Genet* 2012;44:426–9, S1.
23. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1122–6.
24. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1058–60.
25. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. *PLoS Genet* 2009;5:e1000597.
26. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet* 2007;39:638–44.
27. Xu J, Mo Z, Ye D, Wang M, Liu F, Jin G, et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. *Nat Genet* 2012;44:1231–5.
28. Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. *Hum Mol Genet* 2013;22:408–15.
29. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. *Proc Natl Acad Sci U S A* 2010;107:2136–40.
30. Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, et al. Sequence variants at 22q13 are associated with prostate cancer risk. *Cancer Res* 2009;69:10–5.
31. Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers—results from BPC3. *PLoS ONE* 2011;6:e17142.
32. Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, et al. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. *Cancer Sci* 2011;102:1916–20.
33. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. *Nat Genet* 2010;42:751–4.
34. Haiman CA, Han Y, Feng Y, Xia L, Hsu C, Sheng X, et al. Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. *PLoS Genet* 2013;9:e1003419.
35. Batra J, Lose F, Chambers S, Gardiner RA, Aitken J, Yaxley J, et al. A replication study examining novel common single nucleotide polymorphisms identified through a prostate cancer genome-wide association study in a Japanese population. *Am J Epidemiol* 2011;174:1391–5.
36. Liu M, Wang J, Xu Y, Wei D, Shi X, Yang Z. Risk loci on chromosome 8q24 are associated with prostate cancer in northern Chinese men. *J Urol* 2012;187:315–21.
37. Zheng SL, Hsing AW, Sun J, Chu LW, Yu K, Li G, et al. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. *The Prostate* 2010;70:425–32.
38. Yamada H, Penney KL, Takahashi H, Katoh T, Yamano Y, Yamakado M, et al. Replication of prostate cancer risk loci in a Japanese case-control association study. *J Natl Cancer Inst* 2009;101:1330–6.
39. Joung JY, Park S, Yoon H, Lee SJ, Park WS, Seo HK, et al. Association of common variations of 8q24 with the risk of prostate cancer in Koreans and a review of the Asian population. *BJU Int* 2012;110:E318–25.
40. Chen M, Huang Y-C, Yang S, Hsu J-M, Chang Y-H, Huang WJ-S, et al. Common variants at 8q24 are associated with prostate cancer risk in Taiwanese men. *The Prostate* 2010;70:502–7.
41. Cheng I, Chen GK, Nakagawa H, He J, Wan P, Laurie CC, et al. Evaluating genetic risk for prostate cancer among Japanese and Latinos. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol* 2012;21:2048–58.
42. 1000 Genomes Project Consortium Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012;491:56–65.
43. Zakharia F, Basu A, Absher D, Assimes TL, Go AS, Hlatky MA, et al. Characterizing the admixed African ancestry of African Americans. *Genome Biol* 2009;10:R141.
44. So H-C, Gui AHS, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. *Genet Epidemiol* 2011;35:310–7.
45. Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence among relatives. *Ann Hum Genet* 1965;29:51–76.
46. Risch NJ. Searching for genetic determinants in the new millennium. *Nature* 2000;405:847–56.
47. Falconer DS, Mackay TFC. Introduction to quantitative genetics. Essex, England: Longman; 1996.
48. Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. *PLoS ONE* 2011;6:e27130.
49. Witte JS, Visscher PM, Wray NR. The contribution of genetic variants to disease depends on the ruler. *Nat Rev Genet* 2014;11:765–76.
50. Kraft P. Curses—winner's and otherwise—in genetic epidemiology. *Epidemiol Camb Mass* 2008;19:649–51.
51. Lin P-I, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. *Am J Hum Genet* 2007;80:531–8.
52. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000;343:78–85.
53. Visscher PM, Hill WG, Wray NR. Heritability in the genomics era—concepts and misconceptions. *Nat Rev Genet* 2008;9:255–66.
54. Lin H-Y, Amankwah EK, Tseng T-S, Qu X, Chen D-T, Park JY. SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness. *PLoS ONE* 2013;8:e59688.
55. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorf LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. *Nature* 2009;461:747–53.
56. Zheng Y, Ogundiran TO, Falusi AG, Nathanson KL, John EM, Hennis AJM, et al. Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. *Carcinogenesis* 2013;34:1520–8.

Cancer Epidemiology, Biomarkers & Prevention

Replication and Heritability of Prostate Cancer Risk Variants: Impact of Population-Specific Factors

Victor Virlogeux, Rebecca E. Graff, Thomas J. Hoffmann, et al.

Cancer Epidemiol Biomarkers Prev 2015;24:938-943. Published OnlineFirst March 25, 2015.

Updated version Access the most recent version of this article at:
doi:[10.1158/1055-9965.EPI-14-1372](https://doi.org/10.1158/1055-9965.EPI-14-1372)

**Supplementary
Material** Access the most recent supplemental material at:
<http://cebp.aacrjournals.org/content/suppl/2015/03/27/1055-9965.EPI-14-1372.DC1>

Cited articles This article cites 55 articles, 2 of which you can access for free at:
<http://cebp.aacrjournals.org/content/24/6/938.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/24/6/938.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and
Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department
at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/24/6/938>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
Rightslink site.